1.

Record Nr.

UNINA9910842285203321

Titolo

The Heterogeneity of Cancer Metabolism / / edited by Anne Le

Pubbl/distr/stampa

Cham : , : Springer International Publishing : , : Imprint : Springer, , 2018

ISBN

3-319-77736-X

Edizione

[1st ed. 2018.]

Descrizione fisica

1 online resource (186 pages)

Collana

Advances in Experimental Medicine and Biology, , 0065-2598 ; ; 1063

Disciplina

616.99407

Soggetti

Cancer research

Immunology

Cancer Research

Lingua di pubblicazione

Inglese

Formato

Materiale a stampa

Livello bibliografico

Monografia

Nota di contenuto

Part 1: The metabolism of cancer cells -- Chapter 1: Glucose Metabolism -- Chapter 2: Glutamine Metabolism -- Chapter 3: Amino Acid Metabolism -- Chapter 4: Lipid Metabolism -- Chapter 5: Epigenetics and oncometabolites -- Part 2: Heterogeneity of Cancer Metabolism - Chapter 1: Specific oncogenetic mutations lead to specific metabolic phenotypes within the same tissue of origin -- Chapter 2: Intratumoral heterogeneity of cancer cell metabolism  -- - Chapter 3: Differential metabolism in vitro and in vivo -- Part 3: Carcinoma associated fibroblasts -- Chapter 1: Characteristics of CAF's -- Chapter 2: Reverse Warbug EFF -- Chapter 3: Metabolic exchange between CAFs and cancer cells. .

Sommario/riassunto

Genetic alterations in cancer, in addition to being the fundamental drivers of tumorigenesis, can give rise to a variety of metabolic adaptations that allow cancer cells to survive and proliferate in diverse tumor microenvironments. This metabolic flexibility is different from normal cellular metabolic processes and leads to heterogeneity in cancer metabolism within the same cancer type or even within the same tumor. In this book, we delve into the complexity and diversity of cancer metabolism, and highlight how understanding the heterogeneity of cancer metabolism is fundamental to the development of effective metabolism-based therapeutic strategies. Deciphering how cancer cells utilize various nutrient resources will enable clinicians and researchers



to pair specific chemotherapeutic agents with patients who are most likely to respond with positive outcomes, allowing for more cost-effective and personalized cancer therapeutic strategies.